

Figure S1 Patient selection process.




Figure S2 Kaplan-Meier curves and HR for PFS (A and C) and OS (B and D) of NSCLC patients treated with Pembrolizumab. A and B patients stratified by baseline WBC, C and D by NMLR. WBC, white blood cell count; ULN, upper limits of normal; NMLR, neutrophil-monocyte-to-lymphocyte ratio; PFS, progression free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; mo, months.

Table S1 Multivariate analysis for survival outcomes (PFS and OS) with baseline WBC and NMLR.

Parameter	Category	HR	PFS			OS		
			95% CI	p Value	HR	95% CI	p Value	
Age	<75	1.20	0.48- 3.02	0.69	1.18	0.38- 3.70	0.77	
Smoking Status	Never or +10 years former smoker	0.94	0.45- 1.99	0.88	0.97	0.39- 2.40	0.95	
Histological Subtype	Adenocarcinoma	0.98	0.49- 1.97	0.96	1.28	0.57- 2.92	0.55	
ECOG	0-1 (vs ≥2)	0.63	0.28- 1.38	0.25	0.39	0.16- 0.94	0.036*	
WBC	≤ULN	0.43	0.21-0.89	0.02*	0.27	0.11-0.69	0.006*	
NMLR	<6.3	0.19	0.09-0.44	<0.001*	0.07	0.02-0.19	<0.001*	

ECOG, Eastern Cooperative Oncology Group; WBC, white blood cell count; NMLR, neutrophil-monocyte-to-lymphocyte ratio; PFS, progression free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval. *P-values statistically significant